# Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Canonical URL: https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-14-2026
Ticker: LUCD
Company: Lucid Diagnostics
Source: Lucid Diagnostics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.luciddx.com
## Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...

## Article Body
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

Conference Call and Webcast at 8:30 AM ET

, / PRNewswire / -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath , Lucid's Chief Financial Officer, will discuss the Company's first quarter 2026 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com .

About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .

SOURCE Lucid Diagnostics

For further information: Investor and Media Contact: Matt Riley, Vice President, Investor Relations, PAVmed and Lucid Diagnostics, mjr@pavmed.com
## Recent Company News
- 2026-06-25 13:46 EST — [Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-14-2026) — Source: Lucid Diagnostics
- 2026-06-25 13:46 EST — [Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Lucid Diagnostics
- 2026-06-25 13:46 EST — [Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Lucid Diagnostics
- 2026-06-25 13:46 EST — [Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Lucid Diagnostics
- 2026-06-25 13:46 EST — [Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock) — Source: Lucid Diagnostics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)